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Abstract 
Here we report synthetic methodology affording in the most efficient way the rapid preparation of new 
dithiolethiones (DTTs) and methanethiosulfonates (MTSs). These were evaluated as STAT3 inhibitors since 
these electrophilic systems could react with thiol groups of STAT3-SH2 domain. The results showed that MTSs 
strongly interacted with the SH2 domain, whereas the corresponding DTTs possessed lower affinity, 
independently from the nature of the linked heterocyclic scaffold. 
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Introduction 
 
Recent literature
1,2
 shows considerable interest in the chemistry and bioactivity of 1,2-dithiole-3-thiones 
(DTTs) and methanethiosulfonates (MTSs). Both moieties have been reported to exert chemopreventative and 
anticancer activities.
3-7
 Since these electrophilic systems are able to react with thiol groups, and therefore, 
hypothetically, with cysteines in biologically important peptides and proteins,
8,9
 we considered that the 
introduction of these moieties on a suitable scaffold could lead to new inhibitors able to covalently link the 
active site of several transcription factors. A similar behavior was observed between a DTT derivative and 
NFkB (Nuclear Factor Kappa-light-chain-enhancer of activated B cells).
10
 As STAT3 (Signal Transducer and 
Activator of Transcription 3) occupies a noteworthy position in cancer biology,
11
 we decided to explore the 
relevance of these chemical systems against this target. Among the recognized STAT3 direct inhibitors 
reported in the literature many are sulfur-containing compounds, such as sulfones (Stattic),
12
 sulfonates (S31-
201)
13
 or sulfonamides (SF-1-066 and BP-1-102),
13
 but no DTTs or MTSs have been so far considered. As we 
recently published our results on several oxadiazole derivatives able to interfere with the STAT3 signaling 
pathway,
14-17
 we thought it of interest to link this heterocyclic scaffold to DTT and MTS moieties. In this way, 
we aimed to promote the targeting of the new compounds towards the SH2 (Src Homology 2) domain. 
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Figure 1. Structures of the new synthesized compounds. 
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In this paper, we describe synthetic methodology affording in the most efficient way the rapid preparation 
of new inhibitors having DTT or MTS systems linked to differently substituted 1,2,5-oxadiazole rings through 
an ester (1, 4 and 7) or an amidic bond (3, 6 and 8) (Figure 1). In addition, we synthesized the bioisosteric 
analogues of 1 and 4, by replacing the oxadiazole with a substituted N-methylimidazole (2 and 5). 
 
 
Results and Discussion 
 
Chemistry  
The key intermediates for the synthesis of the final products (1-8) were prepared according to the following 
methods. The synthesis of compounds 9, 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoic acid, and 10, 5-
(methylsulfonylthio)pentanoic acid, was achieved following literature procedures.
18,19
 Intermediates 12, 15, 
23, 25 and 27 were prepared as shown in Schemes 1 and 2.
 
The synthesis of 12, bearing a suitable 3-hydroxymethyl substituent, was optimized starting from the 
commercially available para-chlorocinnamic acid to give 11,
20
 the N-oxide moiety of which was removed by 
treatment with trimethyl phosphite
21
 (Scheme 1a). 
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Scheme 1. Reagents and conditions: (a) i) P(OCH3)3, reflux, 18 h; (b): ii) 4-ClC6H4Br, Pd(OAc)2, P(2-furyl)3, 
K2CO3, DMF, 110 °C, 48 h; iii) NaBH4, MeOH, rt, 4 h. 
 
Compound 15 was prepared from 1H-imidazole-4-carbaldehyde, protected as N-methyl derivative by 
iodomethane
22
 (13), then transformed into 14 through a selective palladium-catalyzed C-H activation in 
position 5.
23
 The subsequent reduction step afforded the desired product 15 in good yield (Scheme 1b). 
The intermediates 23, 25 and 27 were synthesized from the appropriate benzaldehyde with some 
variations on the multi-step procedure previously reported
16
 (Scheme 2). Since prolonged (12 hours) 
treatment in refluxing aqueous NaOH of 20a caused an approximately 50% removal of the Boc (tert-
butyloxycarbonyl) group, an additional treatment with tert-butyloxycarbonyl anhydride (Boc2O) was required 
to give 21a. The amides 22 and 24 were obtained by coupling reactions of intermediates 21a,b with 4-
(trifluoromethyl)benzoyl chloride, respectively, while the reaction of compound 21c with 4-nitrobenzoyl 
chloride gave 26. 
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Deprotection of 22 in acidic conditions led to 23; compound 24 was debenzylated by a catalytic 
hydrogenation over Pd/C to 25; compound 26 was reduced in the presence of tin(II) chloride to 27.  
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Scheme 2. Reagents and conditions: i) NH2OH
.
HCl, NaHCO3, MeOH, reflux, 2 h; ii) NCS, DMF, rt, 12 h;  
iii) KCN, Et2O/H2O (2:1), rt, 5 h; iv) NH2OH
.
HCl, NaHCO3 MeOH, reflux, 12 h; v) 2N NaOH, reflux, 12 h; vi) a. 2N 
NaOH, reflux, 12 h; b. Boc2O, DCM, NEt3, rt, 4 h; vii) appropriately substituted benzoyl chloride, 60% NaH, dry 
DMF, 60 °C, 12 h; viii) HCl, dry 1,4-dioxane, rt, 10 min; ix) H2, Pd/C, EtOAc/MeOH (9:1), 24 h; x) SnCl2, EtOAc, 
reflux, 4 h. 
 
The final products 1-8 were prepared by condensation of the suitable intermediate with 9 (Scheme 3) or 
10 (Schemes 4, 5), using different coupling reagents. 
The DTT products 1-3 were obtained in good yields (59-78%) and were easily isolated and purified, thanks 
to their stability and low solubility. 
More difficulties during purification were encountered with all MTS derivatives, which were obtained with 
moderate (28-48%) or low yields (6-7%). 
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Scheme 3. Reagents and conditions: i) EDC*HCl, DMAP, dry DMF, rt, 24 h or 20 h; ii) TBTU, NMM, dry DMF, 
 rt, 20 h. 
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Scheme 4. Reagents and conditions: i) DCC, DMAP, dry CH2Cl2 or dry DMF, rt, 20 h; ii) TBTU, NMM, dry DMF, rt, 
overnight. 
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Scheme 5. Reagents and conditions: i) DCC, DMAP, dry THF, rt, 4 h;  ii) EDC*HCl, DMAP, dry DMF, rt, 24 h. 
 
Biology 
The effects of the final compounds on STAT3 dimerization were determined by the AlphaScreen-based assay,
24
 
an in vitro competitive binding test used to identify compounds able to directly inhibit the binding of SH2-
containing proteins to their correspondent phosphopeptides. To check the selectivity on STAT3, the new 
products were tested also on the highly homologous (78%) STAT1.  
The results showed that MTS derivatives strongly interacted with SH2 domain. Of note, compounds 4 and 7 
inhibited STAT3 dimerization with an IC50 value of 0.6±0.05 µM, though their selectivity versus STAT1 was low 
(IC50 = 5.8±0.3μM and 7.5±0.4μM, respectively). By contrast, the equipotent 6 (IC50 = 0.7±0.04 µM versus 
STAT3) was provided with interesting selectivity (IC50 > 30 µM versus STAT1). The corresponding DTTs (1-3) 
possessed lower affinity (58.7, 26.6 and 33.4% of inhibition at 30 µM, respectively), independently from the 
nature of the linked heterocyclic scaffold. 
In addition, their cytotoxic activity (MTT assay)
25,26
 was tested on HCT116, a human colon carcinoma 
cell line which expresses high levels of STAT3.
27
 Among the assayed compounds, 6 was the most active (IC50 = 
84.5±9.8 µM). Since STAT3 inhibition was tested in a cell-free assay, the low correspondence between STAT3 
inhibition and cytotoxicity could be related to the physicochemical properties of the compounds, which will 
require optimization. 
Based on these data, the MTS moiety appears worth of further investigation for targeting STAT3-SH2 
domain. 
 
 
Conclusion 
 
In our paper, we describe an easy and direct synthetic approach for the preparation of DTT and MTS 
derivatives, bearing a 1,2,5-oxadiazole ring, which has been reported as a promising scaffold for STAT3 
inhibitors. The bioisosteric replacement of the oxadiazole with an N-methylimidazole ring was also considered. 
Due to their better stability, the DTTs (1-3) were obtained in higher yields than the MTSs (4-8). 
The binding efficiency towards STAT3 and STAT1 SH2 domain was evaluated by means of AlphaScreen-
based experiments. In addition, their antiproliferative activity was investigated on HCT116 cancer cell line. The 
biological results showed that MTSs interacted more strongly with SH2 domain with respect to the 
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corresponding DTTs. Although we presume that MTS derivatives can react more easily than DTTs with the free 
thiol group of cysteine residues present in the protein, further studies are required to elucidate the real 
mechanism of inhibition and the different reactivities of MTSs and DTTs. 
In particular, compound 6 showed a higher affinity and selectivity (STAT3 versus STAT1), together with a 
moderate cytotoxic activity. These data suggest that MTS derivatives are promising ligands of the STAT3-SH2 
domain. Optimization of their physicochemical properties is still needed to increase their cytotoxicity. 
 
 
Experimental Section 
 
General. Reagents and solvents were purchased from Sigma-Aldrich and used without further purification. 
Reactions involving air-sensitive reagents were performed under nitrogen atmosphere and anhydrous solvents 
were used when necessary. Reactions were monitored by thin layer chromatography analysis on aluminum-
backed Silica Gel 60 plates (70-230 mesh, Merck), using an ultraviolet fluorescent lamp at 254 nm and 365 nm. 
Visualization was aided by appropriate staining reagents. Purification of intermediates and final compounds 
was performed by flash chromatography using Geduran® Si 60 (40-63 µm, Merck). DMEM (Dulbecco's 
Modified Eagle Medium), trypsin-EDTA, penicillin, streptomycin, non-essential amino acid solution, fetal calf 
serum (FCS), disposable culture flasks and petri dishes were purchased from Euroclone S.p.A. (Pero, Milan, 
Italy).  
1
H and 
13
C NMR spectra were recorded in CDCl3, CD3OD, D2O, DMSO-d6 or acetone-d6 on Bruker DRX Avance 
300 MHz or on a Varian 300 MHz Oxford equipped with a non-reverse probe at 25 
o
C. Chemical shifts are 
expressed as δ (ppm) and were referenced to residual solvent proton/carbon peak. Multiplicity is reported as s 
(singlet), broad s (broad singlet), d (double), t (triplet), q (quartet), m (multiplet), dd (double of doublets), dt 
(doublet of triplets). The coupling constants (J-values) are given in Hertz (Hz). All spectroscopic data match the 
assigned structures. ESI-MS analyses were performed by using a Thermo Finnigan (MA, USA) LCQ Advantage 
system MS spectrometer with an electronspray ionization source and an ‘Ion Trap’ mass analyzer. The MS 
spectra were obtained by direct infusion of a sample solution in methanol under ionization, ESI positive. High-
resolution mass spectra (HRMS) were performed by FT-Orbitrap mass spectrometer in positive electrospray 
ionization (ESI). The melting points were determined on a Buchi Melting Point B540 instrument. 
 
General procedures for the synthesis of dithiolethiones (1-3) and methanethiosulfonates (4-8) 
Procedure A. Compound 12, 15 or 27 (0.1 mmol), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide 
hydrochloride (EDC*HCl, 0.15 mmol) and 4-dimethylaminopyridine (DMAP, 0.02 mmol) were mixed together 
in anhydrous N,N-dimethylformamide (1 mL) and the relevant sulfurated compound (9
18
 or 10
19
, 0.11 mmol) 
was added. The reaction mixture was stirred for 24 h, at rt under an inert atmosphere. The solvent was 
stripped off and the obtained residue was diluted with EtOAc and washed with a cold solution of 0.5 N HCl and 
then with a cold solution of 5% NaHCO3, cold water and brine. The organic layer was dried with anhydrous 
Na2SO4, filtered and evaporated to dryness to get a residue that was purified by flash chromatography (eluent 
as indicated for each compound).  
Procedure B. The appropriate alcohol (12, 15 and 25, 0.13 mmol), N,N'-dicyclohexylcarbodiimide (DCC, 0.14 
mmol) and DMAP (0.01 mmol) were mixed in anhydrous DMF and 5-(methylsulfonylthio)pentanoic acid (10,
19
 
0.14 mmol) was added. The reaction mixture was stirred for 4 or 20 h depending on the involved alcohol 
derivative, at rt under inert atmosphere. After completion, the formed N,N'-dicyclohexylurea was filtered off 
and the solvent was evaporated. The obtained residue was than dissolved in EtOAc or CH2Cl2 and washed with 
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a cold solution of 0.5 N HCl, afterward with a cold solution of 5% NaHCO3, then with cold water and brine. The 
organic layer was dried with anhydrous Na2SO4, filtered and evaporated to dryness to get a residue that was 
purified by flash chromatography or preparative silica-TLC (eluent as indicated for each compound). 
Procedure C. Compound 23 (0.08 mmol) and the correspondent sulfurated compound (9
18
 or 10
19
, 0.09 mmol) 
were mixed together in anhydrous N,N-dimethylformamide (1 mL) under inert atmosphere. After cooling to 
0 °C, N,N,N',N'-Tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate (TBTU, 0.1 mmol) and N-
methylmorpholine (NMM, 0.08 mmol) were added and the reaction mixture was stirred for 24 h at rt. After 
evaporation of the solvent, the residue was taken up with CH2Cl2 or EtOAc and washed with a cold solution of 
0.5 N HCl, a cold solution of 5% NaHCO3, cold water and brine. The organic layer was dried with anhydrous 
Na2SO4, filtered and evaporated to dryness. The obtained solid residue was then rinsed and recrystallized with 
the solvent indicated for each compound. 
[4-(4-Chlorophenyl)-1,2,5-oxadiazol-3-yl]methyl 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoate (1) was synthesized 
according to procedure A using 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoic acid (9) and (4-(4-chlorophenyl)-1,2,5-
oxadiazol-3-yl)methanol (12) in N,N-dimethylformamide. The obtained residue was purified by column 
chromatography (silica gel; CH2Cl2; isocratic). The fractions containing the purified product were gathered up 
and the amorphous solid obtained was crystallized with petroleum ether/CH2Cl2 (2:0.5) and rinsed with the 
same bland to provide the title compound as an orange crystal solid. Yield: 63%. mp 135.2-134.5 °C. 
1
H NMR 
(300 MHz, CDCl3): δH 8.47 (1H, s, CH=C), 8.02 (2H, d, 
3
JHH 8.2 Hz, CH aromatic), 7.72 (2H, d, 
3
JHH 8.2 Hz, CH 
aromatic), 7.62 (2H, d, 
3
JHH 8.2 Hz, CH aromatic), 7.48 (2H, d, 
3
JHH 8.2 Hz, CH aromatic), 5.65 (2H, s, CH2) ppm. 
13
C NMR (75 MHz, DMSO-d6): δC 214.05, 165.24, 161.11, 153.71, 151.14, 147.29, 139.37, 136.64, 130.93, 
130.12, 129.95, 129.82, 128.94, 124.35, 56.65 ppm. HRMS (ESI): m/z calcd for C19H12ClN2O3S3 [M+H]
+
: 
446.9693; found 446.9691. 
[5-(4-Chlorophenyl)-1-methyl-1H-imidazol-4-yl]methyl 4-(3-thioxo-3H-1,2-dithiol-4-yl)-benzoate (2) was 
synthesized according to procedure A using 4-(3-thioxo-3H-1,2-dithiol-4-yl)benzoic acid (9) and (5-(4-
chlorophenyl)-1-methyl-1H-imidazol-4-yl)methanol (15). The crude product was purified by flash 
chromatography (silica gel; CH2Cl2/MeOH; in gradient); the product was eluted with 0.8% of MeOH. The 
obtained amorphous solid was crystallized with EtOAc/Et2O (0.3:1) and rinsed with the same mixture to reach 
the final product obtained as an orange crystalline solid. Yield: 59%. mp 149.9-152.1 °C.
 1
H NMR (300 MHz, 
CDCl3): δH 8.45 (1H, s, CH=C), 8.07 (2H, d, 
3
JHH 8.8 Hz, CH aromatic), 7.59-7.55 (3H, m, CH aromatic), 7.43 (2H, 
d, 
3
JHH 8.8 Hz, CH aromatic), 7.30 (2H, d, 
3
JHH 8.5 Hz, CH aromatic), 5.22 (2H, s, CH2), 3.57 (3H, s, CH3) ppm. 
13
C 
NMR (75 MHz, DMSO-d6): δC 214.10, 165.76, 165.76, 160.97, 147.48, 138.83, 134.07, 133.89, 132.07, 131.26, 
130.12, 129.86, 129.65, 129.51, 128.32, 61.15, 32.84 ppm. HRMS(ESI): m/z calcd for C21H16ClN2O2S3 [M+H]
+
: 
459.0062; found 459.0055. 
[4-(3-Thioxo-3H-1,2-dithiol-4-yl)-N-(4-{4-[4-(trifluoromethyl)benzamido]-1,2,5-oxadiazol-3-
yl}benzyl)benzamide (3) was synthesized according to procedure C using 4-(3-thioxo-3H-1,2-dithiol-4-
yl)benzoic acid (9). The crude product was rinsed three times with a solution of Et2O/CH2Cl2 (1:1) and it was 
isolated as an orange solid. Yield: 78%. mp 119.2-124.5 
o
C. 
1
H NMR (300 MHz, acetone-d6): δH 10.58 (1H, broad 
s, NH exchanged with D2O), 9.10 (1H, s, CH=C), 8.41 (1H, broad s, NH exchanged with D2O), 8.24 (2H, d, 
3
JHH 8.4 
Hz, CH aromatic), 8.00 (2H, d, 
3
JHH 8.6 Hz, CH aromatic), 7.91 (2H, d, 
3
JHH 8.4 Hz, CH aromatic), 7.81 (2H, d, 
3
JHH 
8.6 Hz, CH aromatic), 7.72 (2H, d, 
3
JHH 8.2 Hz, CH aromatic), 7.52 (2H, d, 
3
JHH 8.4 Hz, CH aromatic), 4.68 (2H, d, 
2
JHH 4.2 Hz, CH2) ppm. 
13
C NMR (75 MHz, acetone-d6): δC 214.20, 166.06, 157.71, 151.40, 149.61, 147.73, 
142.70, 136.25, 134.61, 129.02, 128.90, 128.03, 127.61, 127.36, 127.08, 125.70, 124.58, 124.21, 119.07, 
109.40, 42.68 ppm. HRMS (ESI): m/z calcd for C27H18F3N4O3S3 [M+H]
+
: 599.0493; found 599.0497. 
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[4-(4-Chlorophenyl)-1,2,5-oxadiazol-3-yl]methyl 5-(methylsulfonylthio)pentanoate (4) was synthesized 
according to procedure B using [4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl]methanol (12), dissolved in anhydrous 
CH2Cl2. The reaction was stirred for 20 h. The crude product was purified by preparative silica-TLC using 
CH2Cl2/MeOH (96:4) as eluent mixture. The title compound was obtained as a colorless oil. Yield: 35%. 
1
H NMR 
(300 MHz, CDCl3): δH 7.65 (2H, d, 
3
JHH 9 Hz, CH aromatic), 7.51 (2H, d, 
3
JHH 8.7 Hz, CH aromatic), 5.40 (2H, s, 
CH2), 3.31 (3H, s, CH3), 3.14 (2H, t, 
3
JHH 7.3 Hz, CH2COO), 2.39 (2H, t, 
3
JHH 7.3 Hz, SCH2), 1.79-1.72 (4H, m, CH2) 
ppm. 
13
C NMR (75 MHz, CDCl3): δC 172.71, 135.20, 133.62, 131.24, 129.19, 126.69, 60.43, 59.52, 50.74, 47.40, 
36.03, 33.31, 32.55, 28.91, 23.66 ppm. HRMS (ESI): m/z calcd for C15H21ClN3O5S2 [M+NH4]
+
: 422.06057; found 
422.0606. 
[5-(4-Chlorophenyl)-1-methyl-1H-imidazol-4-yl]methyl 5-[(methylsulfonyl)thio]pentanoate (5) was 
synthesized according to procedure B starting from [5-(4-chlorophenyl)-1-methyl-1H-imidazol-4-yl]methanol 
(15), dissolved in anhydrous N,N-dimethylformamide. The reaction mixture was stirred for 20 h. The crude 
product was purified by flash chromatography (silica gel; CH2Cl2/MeOH; in gradient); the product was eluted 
with 0.1% of MeOH. The product was collected as a pale yellow-green oil. Yield: 28%. 
1
H-NMR (300 MHz, 
CDCl3): δH 7.45 (2H, d, 
3
JHH 8.7 Hz, CH aromatic), 7.30 (2H, d, 
3
JHH 9 Hz, CH aromatic), 5.28 (2H, s, CH2), 3.58 (3H, 
s, CH3), 3.31 (3H, s, SO2CH3), 3.14 (2H, t, 
3
JHH 6.9 Hz, CH2COO), 2.39 (2H, t, 
3
JHH 6.9 Hz, SCH2), 1.79-1.72 (4H, m, 
CH2) ppm. 
13
C NMR (75 MHz, CDCl3): δC 171.89, 148.95, 137.35, 129.68, 129.49, 123.66, 54.88, 50.70, 35.81, 
32.96, 29.69, 28.90, 23.40 ppm. HRMS(ESI): m/z calcd for C17H21N2O4S2ClNa [M+Na]
+
: 439.0523; found 
439.0531. 
S-5-Oxo-5-(4-{4-[4-(trifluoromethyl)benzamido]-1,2,5-oxadiazol-3-yl}benzylamino)pentyl methanesulfono-
thioate (6) was synthesized according to procedure C using 5-(methylsulfonylthio)pentanoic acid (10). The 
crude was rinsed three times with pure ethyl ether to give the final product as white-cream crystals. Yield: 
42%. mp 179.4-181.3 °C. 
1
H NMR (300 MHz, acetone-d6): δH 10.55 (1H, broad s, NH exchanged with D2O), 8.25 
(2H, d, 
3
JHH 8.4 Hz, CH aromatic), 7.93 (2H, d, 
3
JHH 8.1 Hz, CH aromatic), 7.78 (2H,d, 
3
JHH 8.1 Hz, CH aromatic), 
7.61 (1H, broad s, NH exchanged with D2O), 7.42 (2H, d, 
3
JHH 8.4 Hz, CH aromatic), 4.43 (2H, d, 
2
JHH 6.0 Hz, CH2), 
3.41 (3H, s, CH3), 3.23 (2H, t, 
3
JHH 6.9 Hz, CH2COO), 2.30 (2H, t, 
3
JHH 6.9 Hz, CH2S), 1.84-1.71 (4H, m, CH2) ppm. 
13
C NMR (75 MHz, acetone-d6): δC 171.82, 165.22, 151.42, 149.73, 142.86, 136.27, 134.21, 128.91, 127.94, 
127.54, 125.73, 124.17, 49.84, 42.19, 35.60, 34.79, 28.93, 24.24 ppm. HRMS (ES
+
): m/z calcd for 
C23H24F3N4O5S2 [M+H]
+
: 557.1140; found 557.1132. 
4-{4-[4-(Trifluoromethyl)benzamido]-1,2,5-oxadiazol-3-yl}phenyl 5-(methylsulfonylthio)pentanoate (7) was 
synthesized according to procedure B using N-(4-(4-hydroxyphenyl)-1,2,5-oxadiazol-3-yl)-4-(trifluoromethyl) 
benzamide (25) dissolved in anhydrous tetrahydrofuran. The reaction mixture was stirred for 4 h. The product 
was purified by flash chromatography (silica gel; EtOAc/cyclohexane in ratio 8:2; isocratic). The fractions 
containing the purified product were gathered up to provide a white solid. Yield: 48%. mp 157.1-158.6 °C. 
1
H 
NMR (300 MHz, acetone-d6): δH 10.59 (1H, broad s, NH exchanged with D2O), 8.25 (2H, d, 
3
JHH 8.4 Hz, CH 
aromatic), 7.95-7.88 (4H, m, CH aromatic), 7.30 (2H, d, 
3
JHH 8.7 Hz, CH aromatic), 3.44 (3H, s, CH3), 3.30 (2H, t, 
3
JHH 7.2 Hz, CH2COO), 2.70 (2H, t, 
3
JHH 7.2 Hz, CH2S), 2.03-1.82 (4H, m, CH2) ppm. 
13
C NMR (75 MHz, acetone-
d6): δC 170.99, 165.24, 152.81, 150.96, 149.95, 136.41, 128.91, 128.89, 125.68, 123.15, 122.58, 49.84, 35.45, 
32.94, 28.93, 23.35 ppm. HRMS (ESI): m/z calcd for C22H21F3N3O6S2 [M+H]
+
: 544.0824; found 544.0816. 
S-5-{4-[4-(4-Chlorophenyl)-1,2,5-oxadiazol-3-ylcarbamoyl]phenylamino}-5-oxopentyl methanesulfono-
thioate (8) was synthesized according to procedure A using 4-amino-N-[4-(4-chlorophenyl)-1,2,5-oxadiazol-3-
yl]benzamide (27) and 5-(methylsulfonylthio)pentanoic acid (10). The crude mixture residue was purified by 
column chromatography (silica gel; EtOAc/cyclohexane; in gradient); the product was eluted with 40% of 
EtOAc. The title compound was obtained as a grey-white solid. Yield: 7%. mp 194.8-198.1 °C. 
1
H NMR (300 
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MHz, acetone-d6): δH 10.28 (1H, broad s, NH exchanged with D2O), 9.51 (1H, broad s, NH exchanged with D2O), 
8.00 (2H, d, 
3
JHH 8.8 Hz, CH aromatic), 7.91-7.80 (4H, m, CH aromatic), 7.55 (2H, d, 
3
JHH 8.8 Hz, CH aromatic), 
3.45 (3H, s, CH3), 3.29 (2H, t, 
3
JHH 6.6 Hz, CH2COO), 2.50 (2H, t, 
3
JHH 6.6 Hz, CH2S), 1.97-1.84 (4H, m, CH2) ppm. 
HRMS (ESI): m/z calcd for C21H22ClN4O5S2 [M+H]
+
: 509.0720; found 509.0712. 
(4-(4-Chlorophenyl)-1,2,5-oxadiazol-3-yl)methanol 2-oxide (11). This intermediate was synthesized according 
to the procedure reported in literature.
20
 Brown oil. Yield 50%. 
1
H NMR (300 MHz, CDCl3) δH 7.79 (2H, d, 
3
JHH 
8.6 Hz, CH aromatic), 7.53 (2H, d, 
3
JHH 8.6 Hz, CH aromatic), 4.73 (2H, s, CH2). 
13
C NMR (75 MHz, CDCl3) δC 
155.81, 137.77, 129.74, 129.06, 124.62, 53.31. MS (ESI) m/z calcd for C9H8ClN2O3 [M+H]
+
: 227.02; found 
227.01. 
(4-(4-Chlorophenyl)-1,2,5-oxadiazol-3-yl)methanol (12).
21
 Compound 11 (1.26 mmol) was refluxed with 
trimethylphosphite (2.62 mL) for 18 h, in a flame-dried flask under nitrogen, monitoring the reaction by TLC 
(cyclohexane/CH2Cl2/EtOAc 5:4.5:0.5). After cooling, 1 N HCl (26.2 mL) was added and the reaction mixture 
was extracted with Et2O. The combined organic layers were washed with saturated NaHCO3, and then with 
brine, dried and evaporated. Flash chromatography (cyclohexane/EtOAc 8:2) was performed to give 12, as 
yellow oil. Yield = 15%. 
1
H NMR (300 MHz, CDCl3) δH 7.86 (2H, d, 
3
JHH 8.4 Hz, CH aromatic), 7.51 (2H, d, 
3
JHH 8.4 
Hz, CH aromatic), 4.98 (2H, s, CH2). 
13
C NMR (75 MHz, acetone-d6) δC 153.42, 153.21, 136.29, 130.19, 129.28, 
124.73, 52.89. MS (ESI) m/z calcd for C9H7ClN2O2Na [M+Na]
+
: 233.01; found 233.6. 
1-Methyl-1H-imidazole-4-carbaldehyde (13). This intermediate was synthesized according to the procedure 
reported in literature.
22
 The final product was collected as a pale-yellow solid. Yield = 65%. 
1
H NMR (300 MHz, 
CDCl3) δH 9.87 (1H, s, CHO), 7.60 (1H, s, CH aromatic), 7.57 (1H, s, CH aromatic), 3.78 (3H, s, CH3). 
13
C NMR (75 
MHz, CDCl3) δC 186.4, 142.9, 139.5, 125.4, 34.2. MS (ES
+
): m/z calcd for C5H7N2O [M+H]
+
: 111.06; found 111.1. 
5-(4-Chlorophenyl)-1-methyl-1H-imidazole-4-carbaldehyde (14).
23
 1-bromo-4-chlorobenzene (1.5 mmol), 
Pd(OAc)2 (0.05 mmol), P(2-furyl)3 (0.1 mmol) and K2CO3 (2.0 mmol) were placed in a reaction vessel under a 
stream of nitrogen. Deaerated 13 (1.0 mmol) and anhydrous N,N-dimethylformamide (5 mL) were then added 
and the resulting mixture was stirred at 110 
o
C for 48 h, monitoring the reaction by TLC (CH2Cl2/MeOH 95:5). 
Once the reaction was complete, the mixture was cooled to rt, diluted with EtOAc/CH2Cl2 (1:1, 30 mL), and 
filtered through Celite. The filtrate was concentrated under reduced pressure and purified by flash 
chromatography with CH2Cl2/MeOH 95:5 as the eluent. The product was obtained as a pale yellow solid. Yield: 
40%. 
1
H NMR (300 MHz, CDCl3) δH 9.80 (1H, s, CHO), 7.62 (1H, s, CH aromatic), 7.50 (2H, d, 
3
JHH 8.43 Hz, CH 
aromatic), 7.36 (2H, d, 
3
JHH 8.43 Hz, CH aromatic), 3.59 (3H, s, CH3) ppm. 
13
C NMR (75 MHz, CDCl3) δC 185.36, 
149.25, 137.87, 131.12, 129.54, 129.33, 128.06, 125.98, 33.78 ppm. MS (ESI): m/z calcd for C11H9ClN2NaO 
[M+Na]
+
: 243.03; found 243.1. 
[5-(4-Chlorophenyl)-1-methyl-1H-imidazol-4-yl]methanol (15). To a solution of 14 (0.5 mmol) in MeOH (5 mL) 
at 0° C, sodium borohydride (0.25 mmol) was added. The reaction was warmed to rt and monitored using TLC 
analysis (eluent CH2Cl2/MeOH 95:5) until the reaction was complete. The mixture was quenched by adding 
water (5 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were dried over Na2SO4, 
filtered and evaporated under reduced pressure. The desired product was obtained as a pale-yellow solid after 
crystallization in CH2Cl2/n-hexane. Yield: 45%. 
1
H NMR (300 MHz, CD3OD) δH 7.68 (1H, s, CH aromatic), 7.49 
(4H, m, CH aromatic), 4.39 (2H, s, CH2), 3.59 (3H, s, CH3) ppm. 
13
C NMR (75 MHz, CD3OD) δC 138.23, 138.04, 
134.52, 131.53, 130.21, 128.75, 127.80, 56.46, 31.61 ppm. MS (ES
+
): m/z calcd for C11H12ClN2O [M+H]
+
: 223.06; 
found 223.1. 
General procedure for the synthesis of benzaldehyde oximes (17a-c). NH2OH·HCl (7.2 mmol) and NaHCO3 
(7.2 mmol) in water (9 mL) were added to a solution of the proper aldehyde 16a-c (6.0 mmol) in MeOH (18 
mL). The mixture was refluxed under stirring for 2 h and the solvent was evaporated under vacuum. The 
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aqueous phase was extracted with EtOAc (3 x 10 mL), the organic solvent dried over Na2SO4 and evaporated 
under reduced pressure to obtain the oximes (17a-b), which were used in the next reaction without further 
purification. 
tert-Butyl-4-[(hydroxyimino)methyl]benzylcarbamate (17a) was synthesized starting from 16a (prepared 
according to literature procedure
28
). White solid. Yield 81%. 
1
H NMR (300 MHz, CDCl3) δH 8.11 (s, 1H, CH), 
7.51-7.24 (m, 4H, CH aromatic), 5.27 (broad s, 1H, NH exchanged with D2O), 4.32 (s, 2H, CH2), 1.47 (s, 9H, 
C(CH3)3) ppm. 
4-Phenoxybenzaldehyde oxime (17b) was synthesized starting from 16b and obtained as white solid. Yield: 
95%. 
1
H NMR (300 MHz, CDCl3) δH 8.18 (1H, s, CH), 7.55 (2H, d, 
3
JHH 9.7, CH aromatic), 7.25-7.45 (5H, m, CH 
aromatic), 7.00 (2H, d, 
3
JHH 9.7, CH aromatic), 5.12 (2H, s, CH2) ppm. 
4-Chlorobenzaldehyde oxime (17c) was synthesized starting from 16c and obtained as white solid. Yield: 95%. 
1
H NMR (300 MHz, CDCl3) δH 8.04 (1H, s, CH), 7.43 (2H, d, 
3
JHH 8.5, CH aromatic), 7.29 (2H, d, 
3
JHH 8.5, CH 
aromatic), 6.67 (broad s, 1H, NOH exchanged with D2O) ppm. 
General procedure for the synthesis of benzoyl chloride oximes (18a-c). The suitable benzaldehyde oxime 
(17a-c, 15 mmol) was dissolved in N,N-dimethylformamide (6 mL) and a first portion of N-chlorosuccinimide 
(NCS, 3 mmol) was added. The reaction mixture was cooled at 0°C and a second amount of NCS (12 mmol) was 
introduced. The solution was stirred for 12h at rt. After addition of water (10 mL) to the reaction mixture, the 
solvent was evaporated under vacuum. The aqueous solution was extracted by EtOAc (3 x 10 mL). The organic 
phases were collected, dried over Na2SO4 and evaporated under vacuum to give the correspondent crude 
hydroxylimino derivative (18a-c), that was directly used without further purification in the next reaction. 
tert-Butyl {4-[chloro(hydroxyimino)methyl]benzyl}carbamate (18a) was synthesized starting from 17a. Pale 
oil. Quantitative yield. 
1
H NMR (300 MHz, CDCl3) δH 8.55 (1H, broad s, NOH exchanged with D2O), 7.75 (2H, d, 
3
JHH 7.8 Hz, CH aromatic), 7.31 (2H, d, 
3
JHH 7.8 Hz, CH aromatic), 4.93 (1H, broad s, NH, exchanged with D2O), 
4.35 (2H, d, 
2
JHH 6.1 Hz, CH2), 1.47 (9H, s, C(CH3)3) ppm. 
4-Benzyloxybenzoyl chloride oxime (18b) was synthesized starting from 17b and obtained as white solid. 
Quantitative yield. 
1
H NMR (300 MHz, CDCl3) δH 8.22 (1H, broad s, NOH exchanged with D2O), 7.78 (2H, d, 
3
JHH 
8.7 Hz, CH aromatic), 7.46-7.29 (5H, m, CH aromatic), 6.98 (2H, d, 
3
JHH 8.7 Hz, CH aromatic), 5.10 (2H, s, CH2) 
ppm. 
4-Chlorobenzoyl chloride oxime (18c) was synthesized starting from 17c and obtained as pale oil. Yield 92%. 
1
H NMR (300 MHz, CDCl3) δH 9.21 (1H, broad s, NOH exchanged with D2O), 7.74 (2H, d, 
3
JHH 8.7 Hz, CH 
aromatic), 7.32 (2H, d, 
3
JHH 8.7 Hz, CH aromatic) ppm. 
General procedure for the synthesis of 2-(hydroxyimino)acetonitriles (19a-c). The required chloride oxime 
(18a-c, 4.8 mmol) was dissolved in Et2O (20 mL) and cooled to 0°C. A solution of KCN (9.6 mmol) dissolved in 
water (10 mL) was added and the reaction mixture was stirred at rt for 5 h. Subsequently the organic layer was 
separated and the aqueous phase was extracted by EtOAc (3 x 10 mL). The organic solvent was dried over 
Na2SO4 and evaporated under reduced pressure to give the crude 2-(hydroxyimino)acetonitriles (19a-c). 
tert-Butyl {4-[cyano(hydroxyimino)methyl]benzyl)}carbamate (19a) was synthesized starting from 18a and it 
was directly used without further purification in the next reaction. Yellow solid. Yield 98%. 
1
H NMR (300 MHz, 
CDCl3) δH 10.15 (1H, broad s, NOH exchanged with D2O), 7.70–7.28 (4H, m, CH aromatic), 5.04 (1H, bs, NH 
exchanged with D2O), 4.37 (2H, s, CH2), 1.47 (9H, s, C(CH3)3) ppm. 
4-Benzyloxyphenyl-2-(hydroxyimino)acetonitrile (19b) was synthesized starting from 18b. The crude was 
purified by flash chromatography (eluting with cyclohexane/EtOAc 9:1) and a white solid was obtained. Yield: 
61%. 
1
H-NMR (300 MHz, acetone-d6) δH 12.36 (1H, broad s, NOH exchanged with D2O), 7.73 (2H, d, 
3
JHH 8.7 Hz, 
CH aromatic), 7.27-7.55 (5H, m, CH aromatic), 7.15 (2H, d, 
3
JHH 8.7 Hz, CH aromatic), 5.20 (2H, s, CH2) ppm. 
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4-Chlorophenyl-2-(hydroxyimino)acetonitrile (19c) was synthesized starting from 18c. The crude was purified 
by flash chromatography (eluting with cyclohexane/EtOAc 9:1) and a yellow solid was obtained. Yield: 87%. 
1
H 
NMR (300 MHz, CDCl3) δH 9.59 (1H, broad s, NOH exchanged with D2O), 7.78 (2H, d, 
3
JHH 9 Hz, CH aromatic), 
7.42 (2H, d, 
3
JHH 9 Hz, CH aromatic) ppm. 
General procedure for the synthesis of acetamidines (20a-c). To a solution of the appropriate intermediate 
(19a-c, 4.7 mmol) in MeOH (13 mL), NH2OH·HCl (7.1 mmol) and NaHCO3 (7.1 mmol) in water (6 mL) were 
added. The mixture was refluxed under stirring for 12 h and the organic solvent was removed under vacuum. 
The aqueous phase was extracted by EtOAc (3 x 10 mL) and the collected organic layers were dried over 
Na2SO4 and evaporated under reduced pressure to give the crude acetamidine intermediates (20a-c), directly 
used without further purification in the next reaction. 
tert-Butyl {4-[2-amino-1,2-bis(hydroxyimino)ethyl]benzyl}carbamate (20a) was synthesized starting from 
19a. White solid. Yield 91%. 
1
H NMR (300 MHz, CD3OD) δH 7.62 (2H, d, 
3
JHH 8.4 Hz, CH aromatic), 7.26 (2H, d, 
3
JHH 8.4 Hz, CH aromatic), 4.23 (2H, s, CH2), 1.45 (9H, s, C(CH3)3) ppm. 
2-[4-(Benzyloxy)phenyl]-N'-hydroxy-2-(hydroxyimino)acetimidamide (20b) was synthesized starting from 19b 
and obtained as light yellow solid. Yield: 99%. 
1
H NMR (300 MHz, acetone-d6) δH 10.80 (1H, broad s, NOH 
exchanged with D2O), 8.94 (1H, broad s, NOH exchanged with D2O), 7.60 (2H, d, 
3
JHH 9.0 Hz, CH aromatic), 
7.45-7.52 (2H, m, CH aromatic), 7.24-7.45 (3H, m, CH aromatic), 7.00 (2H, d, 
3
JHH 9.0 Hz, CH aromatic), 5.45 
(2H, broad s, NH2 exchanged with D2O), 5.16 (2H, s, CH2) ppm. 
2-(4-Chlorophenyl)-N'-hydroxy-2-(hydroxyimino)acetimidamide (20c) was synthesized starting from 19c and 
obtained as white solid. Yield: 95%. 
1
H NMR (300 MHz, CD3OD) δH 7.64 (2H, d, 
3
JHH 8.5 Hz, CH aromatic), 7.34 
(2H, d, 
3
JHH 8.5 Hz, CH aromatic) ppm. 
General procedure for the synthesis of 4-phenyl-1,2,5-oxadiazol-3-amines (21a-c). Each acetamidine 
derivative (20a-c, 4.3 mmol) was dissolved in 2 N NaOH (43 mL) and the solution refluxed under stirring for 12 
h. After cooling, the volume of the mixture was reduced to approximately 10 mL and the so formed precipitate 
was collected by filtration and dried under vacuum. The crude product was then purified as indicated for each 
compound. 
tert-Butyl [4-(4-amino-1,2,5-oxadiazol-3-yl)benzyl]carbamate (21a). The solid obtained from the NaOH 
treatment was then dissolved in CH2Cl2, cooled in an ice bath, and triethylamine (0.8 mmol) followed by tert-
butyloxycarbonyl anhydride (0.8 mmol) were added. The mixture was left 4 hours at rt, after that time the 
solvent was removed under vacuum, the residue dissolved in CH2Cl2and washed with sat. NaHCO3, water and 
brine. The organic solvent was dried over Na2SO4 and evaporated under reduced pressure to give crude 
oxadiazole (21a) which was purified by preparative HPLC (column: SunFire Prep C18 19 x 150 mm, gradient: 
H2O + TFA 0.1% - MeOH + TFA 0.1%). Solid. Yield: 38 %. 
1
H NMR (300 MHz, CD3OD) δH 7.98 (2H, d, 
3
JHH 8.2 Hz, 
CH aromatic), 7.38 (2H, d, 
3
JHH 8.2, CH aromatic), 4.30 (2H, s, CH2), 1.47 (9H, s, C(CH3)3) ppm. 
4-[4-(Benzyloxy)phenyl]-1,2,5-oxadiazol-3-amine (21b) was synthesized starting from 20b and the crude was 
purified by flash chromatography (eluting with cyclohexane/EtOAc 7:3) to give a white solid. Yield: 80%. 
1
H-
NMR (300 MHz, CDCl3) δH 7.66 (2H, d, 
3
JHH 8.8 Hz, CH aromatic), 7.29-7.49 (5H, m, CH aromatic), 7.11 (2H, d, 
3
JHH 8.8 Hz, CH aromatic), 5.14 (2H, s, CH2), 4.19 (2H, broad s, NH2 exchanged with D2O) ppm. 
13
C NMR (75 
MHz, CDCl3) δC 160.67, 154.21, 146.79, 136.49, 129.31, 128.95, 128.47, 127.69, 118.24, 116.01, 70.37 ppm. 
4-(4-Chlorophenyl)-1,2,5-oxadiazol-3-amine (21c) was synthesized starting from 20c and the crude was 
purified by flash chromatography (eluting with cyclohexane/EtOAc 8:2) to afford a white solid. Yield: 38%. 
1
H 
NMR (300 MHz, CDCl3) δH 7.69 (2H, d, 
3
JHH 8.2 Hz, CH aromatic), 7.52 (2H, d, 
3
JHH 8.0 Hz, CH aromatic), 4.21 
(2H, broad s, NH2 exchanged with D2O) ppm. 
13
C NMR (75 MHz, acetone-d6): δC 155.10, 146.20, 135.77, 
129.44, 129.31, 124.95 ppm. 
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General procedure for the synthesis of N-(4-phenyl-1,2,5-oxadiazol-3-yl)benzamides (22, 24, 26). In a two-
necked flame dried flask, 60% NaH mineral oil (0.3 mmol) was suspended in dry N,N-dimethylformamide (3 
mL) under nitrogen. The suspension was cooled in an ice bath and the appropriate key intermediate (21a-c, 
0.25 mmol) was added. The mixture was stirred for 20 min at 0°C. Then, the suitable commercially available 
acyl chloride (0.3 mmol) was added dropwise and the mixture was stirred at 60°C for 12 h. The reaction was 
quenched with water (3 mL) and N,N-dimethylformamide was removed under vacuum. The residue was 
extracted with EtOAc (3 × 2 mL); the organic layer was dried over Na2SO4 and evaporated in vacuo. The crude 
product was purified by column chromatography to obtain the desired adduct.  
tert-Butyl (4-{4-[4-(trifluoromethyl)benzamido]-1,2,5-oxadiazol-3-yl}benzyl)carbamate (22) was synthesized 
starting from 21a and 4-(trifluoromethyl)benzoyl chloride. After purification by preparative HPLC (column: 
SunFire Prep C18 19 x 150 mm, gradient: H2O + TFA 0.1% - MeOH + TFA 0.1%) amide 22 was obtained as a 
white solid. Yield: 33 %. 
1
H NMR (300 MHz, CDCl3) δH 8.66 (1H, broad s, NH exchanged with D2O), 7.99 (2H, d, 
3
JHH 8.1 Hz, CH aromatic), 7.77 (2H, d, 
3
JHH 8.2 Hz, CH aromatic), 7.64 (2H, d, 
3
JHH 8.1 Hz, CH aromatic), 7.39 (2H, 
d, 
3
JHH 8.0 Hz, CH aromatic), 4.99 (1H, t, 
3
JHH 6.1 Hz, NH exchanged with D2O), 4.33 (2H, d, 
2
JHH 6.2 Hz, CH2), 1.44 
(9H, s, C(CH3)3) ppm. 
4-Trifluoromethyl-N-[4-(4-benzyloxyphenyl)-1,2,5-oxadiazol-3-yl]benzamide (24) was synthesized starting 
from 21b and 4-(trifluoromethyl)benzoyl chloride. The crude was purified by flash chromatography (eluting 
with cyclohexane/EtOAc 7:3) affording a white-gray solid. Yield: 30%. 
1
H NMR (300 MHz, CDCl3) δH 8.11 (1H, 
broad s, NH exchanged with D2O), 7.99 (2H, d, 
3
JHH 8.7 Hz, CH aromatic), 7.79 (2H, d, 
3
JHH 8.7 Hz, CH aromatic), 
7.64 (2H, d, 
3
JHH 9.0 Hz, CH aromatic), 7.35-7.44 (5H, m, CH aromatic), 7.09 (2H, d, 
3
JHH 9.0 Hz, CH aromatic), 
5.12 (2H, s, CH2) ppm. 
13
C NMR (75 MHz, CDCl3): δC 136.37 129.36, 129.00, 128.53, 128.32, 127.73, 126.49, 
116.10, 70.37 ppm. 
4-Nitro-N-[4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl]benzamide (26) was synthesized starting from 21c and 4-
nitrobenzoyl chloride. The crude was purified by flash chromatography (eluting from dichloromethane / 
cyclohexane (98:2) to dichloromethane / EtOAc (7:3)) giving a yellow solid. Yield: 46%. mp 229.9-230.2 °C. 
1
H 
NMR (300 MHz, acetone-d6): δH 10.70 (1H, broad s, NH exchanged with D2O), 8.41 (2H, d, 
3
JHH 9 Hz, CH 
aromatic), 8.29 (2H, d, 
3
JHH 9 Hz, CH aromatic), 7.87 (2H, d, 
3
JHH 9 Hz, CH aromatic), 7.56 (2H, d, 
3
JHH 9 Hz, CH 
aromatic) ppm. 
13
C NMR (75 MHz, acetone-d6): δC 165.00, 150.98, 150.69, 149.92, 138.19, 136.50, 129.79, 
129.55, 129.48, 124.87, 123.99 ppm. 
N-[4-(4-Aminomethylphenyl)-1,2,5-oxadiazol-3-yl]-4-(trifluoromethyl)benzamide hydrochloride (23) 
Compound 22 (0.22 mmol) was dissolved with 4 M HCl in 1,4-dioxane (1 mL) at 0 °C. The reaction was stirred 
at rt for 30 minutes. After completion of the reaction, monitored by TLC (CH2Cl2/MeOH 85:15), the solvent was 
stripped off and the formed precipitate was washed with cold Et2O and dried to afford hydrochloride acid salt 
of compound 23. 
4-[4-(4-Hydroxyphenyl)-1,2,5-oxadiazol-3-yl]-4-trifluoromethylbenzamide (25). A solution of 24 (0.54 mmol) 
and catalytic amount of 10% palladium on carbon (10% p/p) in EtOAc (9 mL) and MeOH (1 mL) was 
hydrogenated at rt for 24 hours. The resulting mixture was filtered and extracted with Et2O (3 x 10 mL). The 
organic layer was dried over Na2SO4, filtered and evaporated in vacuum. Under reduced pressure the crude oil 
was purified by flash chromatography eluting with cyclohexane/EtOAc (7:3) to afford the final compound as 
white foam. Yield: 91.5%. 
1
H-NMR (300 MHz, acetone-d6): δH 10.38 (1H, broad s, NH exchanged with D2O), 
8.92 (1H, broad s, OH exchanged with D2O), 8.26 (2H, d, 
3
JHH 9 Hz, CH aromatic), 7.93 (2H, d, 
3
JHH 9 Hz, CH 
aromatic), 7.71 (2H, d, 
3
JHH 9 Hz, CH aromatic), 6.95 (2H, d, 
3
JHH 9 Hz, CH aromatic) ppm. 
13
C NMR (75 MHz, 
DMSO-d6): δC 164.7, 158.5, 147.3, 145.2, 137.5, 134.4, 128.9, 127.8, 125.6, 125.2, 124.1, 116.4 ppm. 
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4-Amino-N-[4-(4-chlorophenyl)-1,2,5-oxadiazol-3-yl]benzamide (27). To a solution of 26 (0.062 mmol) in 
EtOAc (4 mL), tin(II) chloride (0.310 mmol) was added and the mixture was refluxed for 4 h. The reaction was 
then quenched by addition of a saturated aqueous solution of NaHCO3 until pH = 7-8 to allow the precipitation 
of tin salts. The resulting mixture was filtered and washed several times with EtOAc. The aqueous phase was 
extracted with EtOAc (3 × 10 mL). The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. 
The residue was purified on silica gel column chromatography (eluent: cyclohexane/EtOAc 6:4) to give 27 as 
yellow solid. Yield 70 %. mp 153.5-154 °C. 
1
H-NMR (300 MHz, acetone-d6): δH 9.82 (1H, broad s, NH exchanged 
with D2O), 7.64-7.73 (4H, m, CH aromatic), 7.40 (2H, d, 
3
JHH 8.7 Hz, CH aromatic), 6.60 (2H, d, 
3
JHH 8.4 Hz, CH 
aromatic), 5.35 (2H, broad s, NH2 exchanged with D2O) ppm. 
13
C NMR (75 MHz, acetone-d6): δC 166.09, 153.41, 
151.15, 150.88, 136.17, 130.26, 129.36, 129.30, 125.46, 119.84, 113.35 ppm. 
Cell culture. The colorectal HCT116 cell lines were cultured in McCoy’s media supplemented with penicillin 
(10,000 U/mL), streptomycin (10 mg/mL), nonessential amino acid and 10% Fetal Calf Serum (FCS). Cells were 
incubated with newly synthesized compounds dissolved in DMSO. The same volume of solvent was added to 
control conditions and did not exceed 0.5% v/v. 
MTT-assay. The determination of the conversion of MTT (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide) to formazan was determined as previously described.
25,26
 
AlphaScreen-based Assay. The AlphaScreen-based assay was performed according to literature data.
24
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